{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:01:32Z","timestamp":1795024892502,"version":"4.10.2"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.biopha.2021.112000","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T12:48:12Z","timestamp":1629463692000},"page":"112000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer"],"prefix":"10.1016","volume":"142","author":[{"given":"Raquel Santos","family":"Faria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza Ianny","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael Severino","family":"Bonadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Paulo Figueir\u00f3","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie Coimbra","family":"Roque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Nunes","family":"de Matos Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Enrique","family":"Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f4nica Cristina","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Bentes","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112000_bib1","series-title":"Cancer: Principles & Practice of Oncology","author":"Lawrence","year":"2011"},{"key":"10.1016\/j.biopha.2021.112000_bib2","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2021.112000_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1423-0127-19-23","article-title":"Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma","volume":"19","author":"Ho","year":"2012","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.biopha.2021.112000_bib4","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1078-0432.CCR-12-2243","article-title":"New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential","volume":"19","author":"Banerjee","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2021.112000_bib5","doi-asserted-by":"crossref","first-page":"7846","DOI":"10.1158\/0008-5472.CAN-08-1942","article-title":"A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition","volume":"68","author":"Bracken","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2021.112000_bib6","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/ncb1998","article-title":"The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs","volume":"11","author":"Wellner","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.biopha.2021.112000_bib7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s13277-010-0023-y","article-title":"Emerging strategies for the identification and targeting of cancer stem cells","volume":"31","author":"Dou","year":"2010","journal-title":"Tumor Biol."},{"key":"10.1016\/j.biopha.2021.112000_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/science.1234850","article-title":"Epithelial plasticity: a common theme in embryonic and cancer cells","volume":"342","author":"Nieto","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.biopha.2021.112000_bib9","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3390\/cancers30100716","article-title":"Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins?","volume":"3","author":"Kong","year":"2011","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2021.112000_bib10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm3434","article-title":"TGF$\u03b2$ signalling in context","volume":"13","author":"Massagu\u00e9","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2021.112000_bib11","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.4049\/jimmunol.168.12.6470","article-title":"TGF-\u03b21 as an enhancer of Fas-mediated apoptosis of lung epithelial cells","volume":"168","author":"Hagimoto","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2021.112000_bib12","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2021.112000_bib13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2021.112000_bib14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12026-012-8332-4","article-title":"Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse","volume":"52","author":"He","year":"2012","journal-title":"Immunol. Res."},{"key":"10.1016\/j.biopha.2021.112000_bib15","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","article-title":"Phase II study of liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer","volume":"18","author":"Gordon","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2021.112000_bib16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1006\/gyno.2000.5980","article-title":"The clinical utility of liposomal doxorubicin in recurrent ovarian cancer","volume":"81","author":"Campos","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2021.112000_bib17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2147\/DDDT.S156635","article-title":"Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model","volume":"12","author":"Iizuka","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.biopha.2021.112000_bib18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00003088-200342070-00005","article-title":"Pharmacological effects of formulation vehicles: implications for cancer chemotherapy","volume":"42","author":"ten Tije","year":"2003","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.biopha.2021.112000_bib19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1126\/scitranslmed.3007965","article-title":"Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles","volume":"6","author":"Zasadil","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2021.112000_bib20","first-page":"6","article-title":"Paclitaxel (TAXOL\u00ae): side effects and patient education issues","volume":"Vol. 9","author":"Walker","year":"1993"},{"key":"10.1016\/j.biopha.2021.112000_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-016-0172-2","article-title":"NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?","volume":"14","author":"Friberg","year":"2016","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biopha.2021.112000_bib22","unstructured":"D\u00faran, N. Nanotecnologia: introdu\u00e7\u00e3o, prepara\u00e7\u00e3o e caracteriza\u00e7\u00e3o de nanomateriais e exemplos de aplica\u00e7\u00e3o; Artliber, 2006; ISBN 8588098334."},{"key":"10.1016\/j.biopha.2021.112000_bib23","doi-asserted-by":"crossref","first-page":"22951","DOI":"10.1021\/acsami.8b04962","article-title":"Human biomolecular corona of liposomal doxorubicin: the overlooked factor in anticancer drug delivery","volume":"10","author":"Caracciolo","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.biopha.2021.112000_bib24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00280-018-3643-3","article-title":"Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil\u00ae or Caelyx\u00ae in advanced ovarian cancer","volume":"82","author":"Bhowmik","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2021.112000_bib25","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.2147\/DDDT.S211168","article-title":"Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies","volume":"13","author":"Tang","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.biopha.2021.112000_bib26","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/ijms20051042","article-title":"Targeting ovarian cancer cells overexpressing CD44 with immunoliposomes encapsulating glycosylated paclitaxel","volume":"20","author":"Khayrani","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2021.112000_bib27","first-page":"1338","article-title":"Comparative study of first-derivative spectrophotometry and high performance liquid chromatography methods for quantification of paclitaxel in liposomal formulation","volume":"26","author":"Barbosa","year":"2015","journal-title":"J. Braz. Chem. Soc."},{"key":"10.1016\/j.biopha.2021.112000_bib28","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.2147\/IJN.S109966","article-title":"Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis","volume":"11","author":"dos Santos Ferreira","year":"2016","journal-title":"IJN"},{"key":"10.1016\/j.biopha.2021.112000_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-12-200","article-title":"Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy","volume":"12","author":"Gamarra-Luques","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2021.112000_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/pharmaceutics11040178","article-title":"Short and long-term effects of the exposure of breast cancer cell lines to different ratios of free or co-encapsulated liposomal paclitaxel and doxorubicin","volume":"11","author":"Franco","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2021.112000_bib31","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1039\/C9TB00587K","article-title":"Oily core\/amphiphilic polymer shell nanocapsules change the intracellular fate of doxorubicin in breast cancer cells","volume":"7","author":"Coelho","year":"2019","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.biopha.2021.112000_bib32","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2217\/nnm-2017-0091","article-title":"Acid-sensitive lipidated doxorubicin prodrug entrapped in nanoemulsion impairs lung tumor metastasis in a breast cancer model","volume":"12","author":"dos Santos C\u00e2mara","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.biopha.2021.112000_bib33","first-page":"2002","article-title":"Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro","volume":"46","author":"Ganassin","year":"2018","journal-title":"Artif. Cells, Nanomed., Biotechnol."},{"key":"10.1016\/j.biopha.2021.112000_bib34","series-title":"The biology of cancer","author":"Weinberg","year":"2013"},{"key":"10.1016\/j.biopha.2021.112000_bib35","first-page":"45","article-title":"Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy","volume":"7","author":"Goodman","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.biopha.2021.112000_bib36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clbc.2012.05.001","article-title":"Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival","volume":"12","author":"Gradishar","year":"2012","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.biopha.2021.112000_bib37","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.biopha.2018.11.011","article-title":"Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model","volume":"109","author":"Franco","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2021.112000_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbcan.2006.06.004","article-title":"Actions of TGF-$\u03b2$ as tumor suppressor and pro-metastatic factor in human cancer","volume":"1775","author":"Pardali","year":"2007","journal-title":"Biochim. Biophys. Acta (BBA)-Rev. Cancer"},{"key":"10.1016\/j.biopha.2021.112000_bib39","first-page":"6615","article-title":"Enhanced combination therapy effect on paclitaxel-resistant carcinoma by chloroquine co-delivery via liposomes","volume":"10","author":"Gao","year":"2015","journal-title":"Int. J. Nanomed."},{"issue":"5","key":"10.1016\/j.biopha.2021.112000_bib40","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10585-015-9718-1","article-title":"Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation","volume":"32","author":"Ricciardelli","year":"2015","journal-title":"Clin. Exp. Metastas-.-."},{"key":"10.1016\/j.biopha.2021.112000_bib41","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/ncb434","article-title":"Differentiation plasticity regulated by TGF-$\u03b2$ family proteins in development and disease","volume":"9","author":"Derynck","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.biopha.2021.112000_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002325","article-title":"ShcA protects against epithelial-mesenchymal transition through compartmentalized inhibition of tgf-\u03b2-induced smad activation","volume":"13","author":"Muthusamy","year":"2015","journal-title":"PLoS Biol."},{"key":"10.1016\/j.biopha.2021.112000_bib43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4161\/19336918.2014.983794","article-title":"Reprogramming during epithelial to mesenchymal transition under the control of TGF\u03b2","volume":"9","author":"Tan","year":"2015","journal-title":"Cell Adh. Migr."},{"key":"10.1016\/j.biopha.2021.112000_bib44","first-page":"256","article-title":"Transforming growth factor-\u03b2-induced growth inhibition in a Smad4 mutant colon adenoma cell line","volume":"61","author":"Fink","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2021.112000_bib45","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1038\/sj.onc.1206617","article-title":"Inhibition of the antiproliferative effect of TGF \u03b2 by EGF in primary human ovarian cancer cells","volume":"22","author":"Dunfield","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2021.112000_bib46","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1016\/j.biomaterials.2014.01.035","article-title":"Cisplatin\u2013alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells","volume":"35","author":"Wang","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2021.112000_bib47","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/1541-7786.MCR-07-0294","article-title":"Transforming growth factor-$\u03b2$1, transforming growth factor-$\u03b2$2, and transforming growth factor-$\u03b2$3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition","volume":"6","author":"Do","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.biopha.2021.112000_bib48","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1158\/0008-5472.CAN-13-0023","article-title":"TGF-\u03b2 modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment","volume":"73","author":"Yeung","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2021.112000_bib49","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1097\/IGC.0b013e3182a5e760","article-title":"Effect of down-regulated transcriptional repressor ZEB1 on the epithelial-mesenchymal transition of ovarian cancer cells","volume":"23","author":"Chen","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.biopha.2021.112000_bib50","doi-asserted-by":"crossref","first-page":"99482","DOI":"10.18632\/oncotarget.20107","article-title":"Inhibition of ZEB1 leads to inversion of metastatic characteristics and restoration of paclitaxel sensitivity of chronic chemoresistant ovarian carcinoma cells","volume":"8","author":"Sakata","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2021.112000_bib51","doi-asserted-by":"crossref","first-page":"18966","DOI":"10.18632\/oncotarget.3943","article-title":"Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer","volume":"6","author":"Prislei","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2021.112000_bib52","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1101\/gad.1640608","article-title":"The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2","volume":"22","author":"Park","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2021.112000_bib53","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrclinonc.2010.228","article-title":"Mitosis is not a key target of microtubule agents in patient tumors","volume":"8","author":"Komlodi-Pasztor","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2021.112000_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2020.151075","article-title":"Microtubule-targeting agents and their impact on cancer treatment","volume":"99","author":"\u010cerm\u00e1k","year":"2020","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.biopha.2021.112000_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1242\/jcs.189431","article-title":"Microtubules in 3D cell motility","volume":"130","author":"Bouchet","year":"2017","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.biopha.2021.112000_bib56","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3390\/ijms18050971","article-title":"Zampanolide, a microtubule-stabilizing agent, is active in resistant cancer cells and inhibits cell migration","volume":"18","author":"Field","year":"2017","journal-title":"IJMS"},{"key":"10.1016\/j.biopha.2021.112000_bib57","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jconrel.2019.08.034","article-title":"Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: a review article","volume":"311","author":"Khalifa","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2021.112000_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-51419-y","article-title":"Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer","volume":"9","author":"De Clercq","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2021.112000_bib59","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1535-7163.MCT-15-0713-T","article-title":"Paclitaxel-loaded polymersomes for enhanced intraperitoneal chemotherapy","volume":"15","author":"Sim\u00f3n-Gracia","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2021.112000_bib60","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s12094-012-0866-3","article-title":"The EMT signaling pathways in endometrial carcinoma","volume":"14","author":"Colas","year":"2012","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.biopha.2021.112000_bib61","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3390\/jcm8101658","article-title":"Wnt signaling in ovarian cancer stemness, EMT, and therapy resistance","volume":"8","author":"Teeuwssen","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2021.112000_bib62","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.biomaterials.2007.01.014","article-title":"Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles","volume":"28","author":"Lee","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2021.112000_bib63","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jgr.2018.05.005","article-title":"Genotoxicity and subchronic toxicological study of a novel ginsenoside derivative 25-OCH3-PPD in beagle dogs","volume":"43","author":"Zhang","year":"2019","journal-title":"J. Ginseng Res."},{"key":"10.1016\/j.biopha.2021.112000_bib64","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2021.112000_bib65","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/bjc.2015.101","article-title":"IFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer","volume":"112","author":"Abiko","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2021.112000_bib66","first-page":"195","article-title":"The anti-tumoral efficacy of a docetaxel-loaded liposomal drug delivery system modified with transferrin for ovarian cancer","volume":"64","author":"Yuan","year":"2014","journal-title":"Drug Res"},{"key":"10.1016\/j.biopha.2021.112000_bib67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-008-0516-3","article-title":"Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment","volume":"58","author":"Cho","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2021.112000_bib68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ijc.25969","article-title":"Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer\/T-cell lymphoma cells by cell contact-dependent interaction through membrane-bound IL-15","volume":"130","author":"Ishii","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2021.112000_bib69","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1158\/1538-7445.TIM2013-B26","article-title":"Abstract B26: identification of molecular and functional differences in tumor-associated macrophage subsets","volume":"73","author":"Arwert","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2021.112000_bib70","doi-asserted-by":"crossref","first-page":"11041","DOI":"10.1021\/acsnano.8b05189","article-title":"Breast cancer chemo-immunotherapy through liposomal delivery of an immunogenic cell death stimulus plus interference in the IDO-1 pathway","volume":"12","author":"Lu","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.biopha.2021.112000_bib71","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0378-5173(00)00329-X","article-title":"Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds","volume":"200","author":"Perkins","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2021.112000_bib72","doi-asserted-by":"crossref","first-page":"7997","DOI":"10.1007\/s13277-015-3528-6","article-title":"Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells","volume":"36","author":"Liu","year":"2015","journal-title":"Tumor Biol."},{"key":"10.1016\/j.biopha.2021.112000_bib73","first-page":"841","article-title":"Intraperitoneal delivery of a novel liposome-encapsulated paclitaxel redirects metabolic reprogramming and effectively inhibits cancer stem cells in Taxol(\u00ae)-resistant ovarian cancer","volume":"7","author":"Shen","year":"2015","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.biopha.2021.112000_bib74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13046-018-0700-z","article-title":"Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo","volume":"37","author":"Yao","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2021.112000_bib75","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2147\/IJN.S124158","article-title":"Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer","volume":"12","author":"Kim","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2021.112000_bib76","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejps.2015.12.019","article-title":"Biological evaluation of PEG modified nanosuspensions based on human serum albumin for tumor targeted delivery of paclitaxel","volume":"83","author":"Yin","year":"2016","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221007836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221007836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:39:27Z","timestamp":1760099967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221007836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":76,"alternative-id":["S0753332221007836"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112000","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112000"}}